Organogenesis (NASDAQ:ORGO) Given “Sell (D-)” Rating at Weiss Ratings

Organogenesis (NASDAQ:ORGO)‘s stock had its “sell (d-)” rating reiterated by equities research analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

ORGO has been the topic of a number of other research reports. Cantor Fitzgerald boosted their target price on Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. BTIG Research reiterated a “buy” rating and set a $7.00 price target on shares of Organogenesis in a report on Friday, September 26th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Organogenesis has an average rating of “Hold” and an average price target of $7.33.

Organogenesis Stock Performance

ORGO stock opened at $4.26 on Friday. The firm has a 50 day simple moving average of $4.53 and a 200 day simple moving average of $4.18. Organogenesis has a 52 week low of $2.61 and a 52 week high of $6.71. The stock has a market cap of $540.42 million, a P/E ratio of -30.43 and a beta of 1.68.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.08). Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%.The company had revenue of $101.01 million during the quarter, compared to analysts’ expectations of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Sell-side analysts predict that Organogenesis will post -0.07 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ORGO. State of Alaska Department of Revenue bought a new position in shares of Organogenesis in the 3rd quarter valued at approximately $25,000. Hennion & Walsh Asset Management Inc. raised its position in shares of Organogenesis by 69.9% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 158,740 shares of the company’s stock valued at $670,000 after purchasing an additional 65,333 shares during the period. Regent Peak Wealth Advisors LLC bought a new position in shares of Organogenesis in the third quarter valued at approximately $51,000. Voya Investment Management LLC lifted its stake in shares of Organogenesis by 477.4% in the third quarter. Voya Investment Management LLC now owns 115,259 shares of the company’s stock worth $486,000 after buying an additional 95,296 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Organogenesis by 69.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company’s stock worth $20,488,000 after buying an additional 1,997,038 shares during the period. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.